Videos

Martinez discusses unmet needs in pruritus management and maralixibat’s potential to expand treatment of itch across rare cholestatic liver diseases.

Study reveals chronic pain reshapes hippocampus, driving depression risk. Microglia may be a therapeutic target, says Xiao.

Accelerated rTMS shows comparable efficacy to standard care, with delayed response in some patients and no clear predictors of early benefit.

In this episode of the Skin of Color Savvy podcast, 2 leaders in dermatology discuss the complexities of colorism and its impact on pigmentary disorders.

A metabolic polygenic risk score built from 20 traits and more than 8.5 million individuals outperformed existing disease-prediction models.

New study finds GLP-1 RAs are associated with lower anxiety, suicidality, and sick leave in patients with diabetes and mental illness.

Phase 3 VITESSE data show VIASKIN peanut patch improves tolerance in most children, with high adherence and a favorable safety profile.

After the oral IL-23 inhibitor icotrokinra's (Icotyde) FDA approval, this interview covers what primary care clinicians should conclude.

Linda Stein Gold, MD, shares her perspective on the clinical significance of icotrokinra's FDA approval and what dermatologists need to know.

Kichler notes that EPI is frequently overlooked in patients with symptoms resembling IBD or celiac disease and offers key insights on diagnosis and management.

Shamji shared the factors influencing which treatments are best for each patient and further research he'd like to see.

Meta-analysis shows psychedelic-assisted therapy offers similar symptom improvement to open-label antidepressants under equal unblinding conditions.

AI-enabled ECG may help detect liver disease earlier, offering a new path to close diagnostic gaps and shift toward preventive hepatology in clinical practice.

Su described how NNAALs drive management decisions in pregnancy and post partum care.

Accelerated 5×5 rTMS delivers comparable outcomes to standard protocols, offering faster treatment with key tradeoffs in cost, access, and response timing.

Neuen reflects on new FIND-CKD data suggesting finerenone’s benefit in nondiabetic chronic kidney disease and highlights urgency of early screening and combination therapy.

Data from 39 kidney biopsies may challenge longterm beliefs about diabetic nephropathy in CKD.

In a rapidly evolving therapeutic landscape, how can clinicians make decisions to personalize IgAN care?

Le discusses the AHA/ACC clinical guidelines for the management of dyslipidemia, highlighting the shifting attitude towards hypertriglyceridemia treatment.

This discussion reflects on great speakers, the unique pressures women face on the podium, and what it takes to build a national platform in academic medicine.

Le discusses the AHA/ACC clinical guidelines for the management of dyslipidemia, highlighting the return of LDL-C target goals for ASCVD prevention.

High costs, limited insurance coverage, and adherence challenges remain key barriers to broader SLIT use in the US, Larenas-Linnemann says in an interview at AAAAI 2026.

Allocating lower but acceptable quality kidneys to high-risk patients could introduce equity.

This segment of the latest episode of The Medical Sisterhood highlights insights into the career of Natasha Mesinkovska, MD, PhD.

At AAAAI 2026, Ramsey discussed the shift toward race-neutral spirometry equations, their clinical implications, and barriers to widespread adoption.

Even Routine Urinalysis Can Reveal Hidden IgA Nephropathy, Especially in Young Adults

Le discusses the AHA/ACC clinical guidelines for the management of dyslipidemia, highlighting PREVENT and a renewed focus on Lp(a).